The Potential of Electroencephalography (EEG) and Magneto encephalography (MEG) in Studying Brain Dynamics.

Spake Hambäck*

Department of Health Psychology, University of Brunel, United Kingdom

Introduction

Schizophrenia and Bipolar Disorder are complex psychiatric conditions characterized by disturbances in mood, cognition, and perception. While the underlying neurobiological mechanisms of these disorders are still not fully understood, recent advancements in neuroimaging techniques have provided valuable insights into the dynamic brain processes associated with these conditions. Electroencephalography (EEG) and Magnetoencephalography (MEG) are non-invasive imaging techniques that offer unique advantages in studying brain dynamics and neural oscillations in schizophrenia and bipolar disorder [1,2].

Schizophrenia and Bipolar Disorder are severe mental illnesses that significantly impact individuals' lives and pose substantial challenges for treatment and management. Schizophrenia is characterized by hallucinations, delusions, disorganized thinking, and impaired social functioning. Bipolar Disorder involves periods of depression alternating with episodes of mania or hypomania, along with fluctuations in mood, energy, and activity levels. Despite differences in symptomatology, both disorders share overlapping neurobiological features and are thought to involve dysregulation of neural circuits and neurotransmitter systems in the brain [3,4].

Electroencephalography (EEG) and Magnetoencephalography (MEG) are neuroimaging techniques that provide real-time measurements of neuronal activity and brain dynamics with high temporal resolution. EEG records electrical activity generated by neurons using electrodes placed on the scalp, while MEG detects magnetic fields produced by neuronal currents using sensors placed outside the head. Together, EEG and MEG offer complementary information about the spatiotemporal dynamics of neural oscillations, synchronization, and connectivity in the brain [5].

EEG and MEG studies have revealed alterations in brain dynamics and neural oscillations in individuals with schizophrenia. Abnormalities in gamma-band oscillations, particularly during cognitive tasks, have been consistently observed in schizophrenia and are thought to reflect disturbances in cortical network synchronization and information processing. Additionally, disruptions in the balance of excitation and inhibition, as reflected by alterations in alpha and beta-band oscillations, have been implicated in sensory gating deficits and cognitive dysfunction in schizophrenia. EEG and MEG offer valuable insights into the pathophysiology of schizophrenia and may help identify biomarkers for diagnosis and treatment response [6,7].

The use of MRS to investigate neurochemical alterations in mood disorders has important implications for diagnosis, treatment, and prognosis. Neurochemical biomarkers derived from MRS data may aid in the early detection and differential diagnosis of mood disorders, particularly in cases where symptoms overlap with other psychiatric conditions. Moreover, MRS-guided interventions, such as pharmacological treatments targeting specific neurotransmitter systems or neuromodulator techniques, hold promise for personalized treatment approaches tailored to individual neurochemical profiles [8].

Despite its promise, MRS research in mood disorders faces several challenges, including sample heterogeneity, small sample sizes, and methodological variability across studies. Moreover, the interpretation of MRS findings in mood disorders is complex, as alterations in neurochemical concentrations may reflect a combination of genetic, environmental, and neurobiological factors. Moving forward, larger-scale multicenter studies, standardized imaging protocols, and longitudinal assessments will be essential for advancing our understanding of neurochemical alterations in mood disorders and their relationship to clinical outcomes [9,10].

Conclusion

Electroencephalography (EEG) and Magneto encephalography (MEG) offer promising avenues for advancing our understanding of the intricate brain dynamics underlying Schizophrenia and Bipolar Disorder. Through their high temporal resolution and non-invasive nature, EEG and MEG enable the real-time measurement of neuronal activity, oscillations, and connectivity patterns in individuals with these psychiatric conditions. EEG and MEG studies have revealed significant alterations in brain dynamics, including aberrant neural oscillations, synchronization deficits, and connectivity disturbances, which are associated with the pathophysiology of Schizophrenia and Bipolar Disorder.

References

1. Bigdeli TB, Harvey PD. Genetics Of Bipolar Disorder And Schizophrenia. Neuroimaging Gen. 2022:238.

***Correspondence to:** Spake Hambäck, Department of Health Psychology, University of Brunel, United Kingdom, E-mail: hambackspake@brunel.uk

***Received:** 02-Dec-2024, Manuscript No. AACPCP-24-135621; **Editor assigned:** 04-Dec-2024, Pre QC No. AACPCP-24-135621 (PQ); **Reviewed:** 16-Dec-2024, QC No. AACPCP-24-135621; **Revised:** 23-Dec-2024, Manuscript No. AACPCP-24-135621(R); **Published:** 30-Dec-2024, DOI:10.35841/aacpcp-7.4.165*

***Citation:** Hambäck S. The Potential of Electroencephalography (EEG) and Magneto encephalography (MEG) in Studying Brain Dynamics. J Clin Psychiatry Cog Psychol 2024; 7(4):165*

2. Mullins N, Bigdeli TB, Børglum AD. GWAS of suicide attempt in psychiatric disorders and association with major depression polygenic risk scores. Am J Psychiatry. 2019;176(8):651-60.

3. Gupta R, Bigdeli TB, Buckley PF . Genetics of Schizophrenia and Bipolar Disorder: Potential Clinical Applications. Psychiatr Ann 2021;51(4):158-64.

4. Ni G, Zeng J, Revez JA, et al. A comparison of ten polygenic score methods for psychiatric disorders applied across multiple cohorts. Biol Psychiatry. 2021;90(9):611-20.

5. O'donovan MC, Craddock N, Norton N. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Gen. 2008;40(9):1053-5.

6. Kane JM, Schooler NR, Marcy P. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Pychiatry. 2020;77(12):1217-24.

7. Fleischhacker WW, Hobart M, Ouyang J. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2017;20(1):11-21.

8. Stauffer VL, Millen BA, Andersen S. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophrenia Res. 2013;150(2-3):434-41.

9. Wykes T, Huddy V, Cellard C. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472-85.

10. Moritz S, Andreou C, Schneider BC. Sowing the seeds of doubt: a narrative review on metacognitive training in schizophrenia. Clin Psychol Rev. 2014;34(4):358-66.

Citation: *Hambäck S. The Potential of Electroencephalography (EEG) and Magneto encephalography (MEG) in Studying Brain Dynamics. J Clin Psychiatry Cog Psychol 2024; 7(4):165*